Dynavax Technologies Corporation (DVAX) President & COO Holds 64066.0 Worth Of Stock

The stock of Dynavax Technologies Corporation (NASDAQ:DVAX) decreased by decreased by -$0.73 on Friday to finish at $18.12, down -3.87 percent. The last five days have seen an average of 2,815,500 shares of common stock traded. 28 times new highs were reached in the current year, with a gain of $13.67. The average number of shares traded over the last 20 days was 3,001,185, while the average volume over the last 50 days totaled 5,394,708.

DVAX stock dropped -7.55% since last month. On 10/01/21, the company’s shares reached a one-month low of $15.86. The stock touched a high of $20.96 on 09/27/21, after rallying from a low of $3.58 in 52 weeks. The price of DVAX stock has risen by 307.19% or $13.67 this year, reaching a new high 28 times. Still, the stock price is down -13.55% from the 52-week high.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


Insider Transactions

There have been 18 days since Dynavax Technologies Corporation (DVAX) last reported insider trading activity on Oct 07. On Oct 07, President & COO Novack David F sold 3,000 shares at $18.00 each. This transaction resulted in the insider making $54,000. On Oct 01, Novack David F sold 17,000 shares at a price of US$18.23. After the transaction, the insider now owns 67,066 shares. Senior Vice President Janssen Robert had earlier sold 900 shares on Sep 01 for $20.15 a share. The transaction was completed for $18,135.

Valuation Metrics

Beta for the stock is 1.24. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 12.79, the price-to-book (PB) ratio of 24.82, and the price-to-cash flow ratio of 21.31.

For the three months ended June 29, Dynavax Technologies Corporation’s quick ratio was 2.40, while its current ratio was 2.90, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 2.64, and the total debt to equity ratio is 2.64. As far as profitability goes, gross margin for the trailing twelve months is 71.90% percent. Dynavax Technologies Corporation’s EBITDA margin for the year ended June 29 was -141.54%, whereas its operating margin stood at 4.00% for the same period. Based on annual data, it had gross profit of $35.14 million and revenue of $46.55 million.

Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. DVAX’s return on assets (ROA) during the last 12 months has been -1.20%. There was a -28.70% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -7.30%. ROE has averaged -15.50 in the past year for the broader industry.

Earnings Surprise

According to Dynavax Technologies Corporation’s quarterly financial report for the quarter that ended June 29, it had $216.2 million in cash and short-term investments. A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $52.77 million, while revenues rose by 94.94% to $83.34 million. It was predicted that Dynavax Technologies Corporation’s quarterly earnings would be $0.02, but it ended up being -$0.04. EBITDA was $11.09 million for the quarter. At the end of Dynavax Technologies Corporation’s most recent quarter ended June 29, its liabilities totaled 564.53 million, while its total debt was $256.34 million. Equity owned by shareholders amounts to $114.76 million.

Technical Picture

Here’s a quick look at Dynavax Technologies Corporation’s (DVAX) price momentum from a technical perspective. As of 22 October, the RSI 9-day stood at 54.42%, suggesting the stock is Neutral, with a 45.16% historical volatility rate.

The stochastic %K and %D were 78.90% and 65.29% respectively, while the average true range (ATR) was 1.27. Based on the 14-day stochastic reading of 64.49%, the RSI (14) reading is 54.59%. On the 9-day MACD Oscillator, the stock is at 0.69, and the 14-day reading is at 0.69.

Analyst Ratings

In its analyst report released on August 06, 2021, Goldman began covering Dynavax Technologies Corporation (NASDAQ: DVAX). The stock was rated as a Buy by the brokerage firm. Analysts have assigned Dynavax Technologies Corporation (DVAX) an Buy rating. DVAX is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 4 others recommend it as a buy.

What is DVAX’s price target for the next 12 months?

The current consensus forecast for the stock is between $20.00 and $23.00, with a median target price of $22.00. In analyzing these forecasts, the average price target given by analysts for Dynavax Technologies Corporation (DVAX) is $21.67.


Please enter your comment!
Please enter your name here


Hot Topics

Related Videos

Related Videos

Related Articles



Download Free eBook For



100% free. stop anytime no spam